NCT00744237
Study of the Glycemic Effects of Nebivolol Compared With Metoprolol and HCTZ in Diabetic Hypertensive Patients
See it on ClinicalTrials.gov ↗230 people
38.7%
61.3%
89 womenmiddle line = equal numbers141 men
- Phase
- PHASE4
- Paid for by
- Forest Laboratories
- Finished
- —
- Health conditions
- Hypertension, Type 2 Diabetes Mellitus
- Who could join
- Anyone
- Ages
- 18 Years – 85 Years
- Average age
- mean 58.9 years
- Age 65+
- 28.3%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Active liver disease as determined by lab markers”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“History of heart attack, clinically significant arrhythmia, unstable angina, coronary angioplasty/bypass surgery, stroke, or TIA in 3 months prior to screening”
Study titles and rules are shown in their original English.